Advances in the development of molecular tools for the control of bovine babesiosis in Mexico
- PMID: 17691602
Advances in the development of molecular tools for the control of bovine babesiosis in Mexico
Abstract
The severe negative impact that bovine babesiosis has in the Mexican cattle industry has not been ameliorated basically due to the lack of safe and effective commercially available vaccines and sensitive and reliable diagnostic tests. In recent years, the Bovine Babesiosis Laboratory at the National Center for Disciplinary Research in Veterinary Parasitology-INIFAP in Morelos State, Mexico has been directing efforts towards three main research areas: (1) The development of in vitro culture-derived, improved and safer live vaccines. This has been done in two ways: using gamma-irradiated bovine serum and erythrocytes for the in vitro culture of vaccine strains, which reduces the risk of contaminating pathogens, and improving the immune response, by the addition of L. casei, a strong stimulant of the innate immune system. (2) The study of antigens considered as vaccine candidates with the goal of developing a recombinant vaccine that suits the country's needs. Knowing their degree of conservation or variation in Mexican isolates, their phylogenetic relationship and their protective, immuno-stimulatory properties, are first steps towards that goal. (3) The development of new tools for diagnosis, detection and discrimination of bovine babesiosis is the third area. Developing variants of ELISA, which are more reliable than the currently used IFAT, are a priority, and finally, taking advantage of the genomes of Babesia bigemina, and B. bovis, we are identifying genes than allow us to discriminate isolates using molecular tools.
Similar articles
-
Search for Babesia bovis vaccine candidates.Parassitologia. 2007 May;49 Suppl 1:9-12. Parassitologia. 2007. PMID: 17691600 Review.
-
Field challenge of cattle vaccinated with a combined Babesia bovis and Babesia bigemina frozen immunogen.Ann N Y Acad Sci. 2004 Oct;1026:277-83. doi: 10.1196/annals.1307.043. Ann N Y Acad Sci. 2004. PMID: 15604506 Clinical Trial.
-
Efficiency of a recombinant MSA-2c-based ELISA to establish the persistence of antibodies in cattle vaccinated with Babesia bovis.Vet Parasitol. 2008 Nov 7;157(3-4):203-10. doi: 10.1016/j.vetpar.2008.07.025. Epub 2008 Aug 5. Vet Parasitol. 2008. PMID: 18783887
-
Vaccination of older Bos taurus bulls against bovine babesiosis.Vet Parasitol. 2005 May 15;129(3-4):235-42. doi: 10.1016/j.vetpar.2005.01.013. Vet Parasitol. 2005. PMID: 15845278
-
Prospects for recombinant vaccines against Babesia bovis and related parasites.Parasite Immunol. 2006 Jul;28(7):315-27. doi: 10.1111/j.1365-3024.2006.00849.x. Parasite Immunol. 2006. PMID: 16842268 Review.
Cited by
-
The GP-45 Protein, a Highly Variable Antigen from Babesia bigemina, Contains Conserved B-Cell Epitopes in Geographically Distant Isolates.Pathogens. 2022 May 18;11(5):591. doi: 10.3390/pathogens11050591. Pathogens. 2022. PMID: 35631112 Free PMC article.
-
Babesia bovis Enolase Is Expressed in Intracellular Merozoites and Contains B-Cell Epitopes That Induce Neutralizing Antibodies In Vitro.Vaccines (Basel). 2025 Jul 31;13(8):818. doi: 10.3390/vaccines13080818. Vaccines (Basel). 2025. PMID: 40872905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical